Victoria Kong

Victoria Kong

Auto-generated profile, based on publicly available information

Victoria Kong

Department of Surgery, Division of Plastic and Reconstructive Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, CT, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2024 in Cancers
Verified
Journal Article
Open access
SRSyed Nahiyaan Rahman
Syed Nahiyaan Rahman
VKVictoria Kong
Victoria Kong
MJMichael Jalfon
Michael Jalfon
DHDavid Hesse
David Hesse
JKJoseph Kim
Joseph Kim
FGFady Ghali
Fady Ghali
Background: Plasmacytoid urothelial carcinoma (PUC) is a rare histologic subtype of urothelial carcinoma of the bladder (BC). Our objective was to characterize treatment patterns and outcomes of PUC in the NCDB and our recent institutional experience. Methods: The NCDB was queried for localized PUC cases between 2004 and 2020. Patients with PUC from a single institution (Yale School of Medicine) were also incorporated from 2021 onwards to not double-count patients. The primary outcomes were overall survival and treatment trends. Results: A total of 146 patients were included, 123 from NCDB and 23 from Yale. The median overall survival (mOS) was 28 [IQR 7.5, 50.3] months, 23 [IQR 8.4, 46.3] months for the NCDB patients, and 36 [IQR 4.3, 68.1] for the Yale patients. The mOS for patients receiving neoadjuvant chemotherapy (NAC) was 60.0 [28.0, 91.9] vs. 14.8 months [0, 34.3] for patients without NAC, p = 0.038, though the benefit was not preserved in a Cox proportional hazard analysis incorporating the clinical stage, receipt of NAC, and age. The peritoneum was the most common site of metastasis (78.3%), followed by the liver and bones. Conclusion: Our findings underscore the formidable challenge posed by PUC, emphasizing its limited response to current therapies. Despite higher pT0 rates with NAC, the OS benefit remains inconclusive, highlighting the need for more effective treatments.

18 February 2026 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
VKVictoria Kong
Victoria Kong
ASAndrew Salib
Andrew Salib
JSJoshua Sanchez
Joshua Sanchez
OAOmar Allam
Omar Allam
MKMartin Kauke-Navarro
Martin Kauke-Navarro
MAMichael Alperovich
Michael Alperovich

8 May 2026 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
VKVictoria Kong
Victoria Kong
ASAndrew Salib
Andrew Salib
KBKaren Bach
Karen Bach
MRMohamed A. Ramy
Mohamed A. Ramy
GAGrace Allen
Grace Allen
PBParis D. Butler
Paris D. Butler

30 October 2026 in Aesthetic Surgery Journal Open Forum
Verified
Journal Article
Open access
TSThomas Schaschinger
Thomas Schaschinger
FKFelix J Klimitz
Felix J Klimitz
AFAdriano Fabi
Adriano Fabi
VKVictoria Kong
Victoria Kong
ASAndrew Salib
Andrew Salib
SKSamuel A Knoedler
Samuel A Knoedler
Background: Hypertension has a global prevalence of over 30% in the adults and is associated with adverse surgical outcomes. However, its specific impact on postoperative complications in cosmetic abdominoplasty remains underexplored. Objectives: To evaluate the association between medically treated hypertension and 30-day postoperative complications following elective cosmetic abdominoplasty. Methods: The ACS-NSQIP database (2008-2022) was retrospectively analyzed for adult patients undergoing elective cosmetic abdominoplasty. All patients were categorized into two groups: those medically treated for hypertension (MedHyp) and those without (NoMedHyp). Univariate analysis, multivariate logistic regression, and propensity score matching (PSM) evaluated 30-day postoperative outcomes. Results: Of 1,791 patients, 1,457 (81%) were NoMedHyp group (mean age: 43.9 ± 10.5 years; BMI: 28.2 ± 5.8 kg/m2) and 334 (19%) MedHyp (mean age: 52.5 ± 10.6 years; BMI: 31.1 ± 6.2 kg/m2; both p < 0.001). The overall complication rate was 6.0% (n = 107), with 4.8% (n = 70) in NoMedHyp and 11% (n = 37) in MedHyp (p < 0.001). Multivariate analysis showed hypertension was significantly associated with increased odds of overall (OR: 2.35, p < 0.001) and surgical complications (OR: 2.91, p < 0.001), including deep incisional infections (OR: 4.67, p = 0.04) and bleeding requiring transfusion (OR: 6.81, p < 0.001). After PSM (balancing age, BMI, and race), hypertension remained significantly associated with higher overall (OR: 3.08, p < 0.001) and surgical complications (OR: 3.44, p = 0.003), including bleeding requiring transfusion (OR: 9.22, p = 0.04). Conclusions: Hypertension is a significant risk factor for postoperative complications in cosmetic abdominoplasty, particularly for surgical complications and bleeding.

7 May 2026 in Journal of Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
ASAndrew Salib
Andrew Salib
VKVictoria Kong
Victoria Kong
WBWilliam Bai
William Bai
OAOmar Allam
Omar Allam
JGJonathan N Grauer
Jonathan N Grauer
MAMichael Alperovich
Michael Alperovich

19 August 2026 in Journal of Cosmetic Dermatology
Verified
Journal Article
Open access
BBBruna Bravo
Bruna Bravo
ASAna Luísa Leopoldino de Souza
Ana Luísa Leopoldino de Souza
VKVictoria Kong
Victoria Kong
LKLeonard Knoedler
Leonard Knoedler
MAMichael Alfertshofer
Michael Alfertshofer
SCSUELI CARNEIRO
SUELI CARNEIRO
Background: Gender‐affirming facial procedures alleviate dysphoria, yet prospective data on nonsurgical interventions remain scarce. Objective data on anatomical and psychosocial outcomes following injectable fillers in transgender populations are poorly defined. Aims: To quantitatively evaluate soft‐tissue changes and psychosocial outcomes following gender‐affirming facial contouring with hyaluronic acid (HA) fillers. Patients/Methods: In this prospective, single‐center study, 50 transgender patients (25 trans women and 25 trans men) underwent individualized HA filler treatments. Three‐dimensional (3D) stereophotogrammetry was performed using a VECTRA (Canfield Scientific, Parsippany, NJ, USA) to assess facial soft‐tissue changes at baseline and 30 days post‐treatment. Linear distances were measured on 3D facial images using the VECTRA Analysis Module software with integrated digital caliper tools. Psychosocial outcomes were measured using validated Likert‐type measures of satisfaction and gender identification, including the Global Aesthetic Improvement Scale (GAIS). Results: Mean injected volume was 9.8 ± 3.5 mL and was well tolerated, with no serious adverse events. Satisfaction and gender identification scores improved significantly (Δ + 1.53 and + 1.71, respectively; both p < 0.001). The 3D analysis demonstrated significant, directionally gender‐congruent changes. Trans women showed increases in bizygomatic width (+ 3.75 mm) and labial height (+ 1.77 mm), along with a reduction in perceived chin width (−12.94 mm). Trans men exhibited increases in bigonial width (+ 5.04 mm) and chin width (+ 4.53 mm) (all p < 0.001). Despite millimeter‐scale changes, these modifications were associated with substantial psychosocial improvement. Conclusions: This prospective study demonstrated measurable, gender‐congruent changes in facial morphology following injectable HA filler treatment, accompanied by improvements in patient‐reported satisfaction and gender identification. Despite similar injected volumes, anatomical effects differed between groups, reflecting strategic three‐dimensional redistribution of soft tissue rather than volume alone. These findings support nonsurgical facial contouring as an effective approach for gender affirmation.